Skip to main content

Advertisement

Table 2 Double-blind baseline demographics and clinical characteristics

From: Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies

  Study active arms Study placebo arms
PP Paliperidone ER PP placebo Paliperidone ER placebo
  (n= 193) (n= 104) (n= 192) (n= 101)
Age in years, mean (SD) 38.6 (11.4) 39.0 (10.7) 39.2 (10.8) 37.5 (10.4)
Sex, n (%)     
  Male 104 (53.9) 58 (55.8) 104 (54.2) 63 (62.4)
  Female 89 (46.1) 46 (44.2) 88 (45.8) 38 (37.6)
Race, n (%)     
  Caucasian 124 (64.3) 62 (59.6) 126 (65.6) 61 (60.4)
  Black 36 (18.7) 8 (7.7) 35 (18.2) 9 (8.9)
  Asian 30 (15.5) 3 (2.9) 27 (14.1) 0
  Other 3 (1.6) 31 (29.8)a 4 (2.1) 31 (30.7)a
Age at diagnosis in years, mean (SD) 26.3 (9.2) 27.1 (9.2) 28.2 (8.9) 25.8 (9.4)
Baseline PANSS total score, mean (SD) 50.8 (11.0) 51.0 (11.4) 51.9 (11.1) 53.4 (10.6)
Baseline CGI-S score, n (%)     
  Not ill 11 (5.7) 6 (5.8) 11 (5.7) 5 (5.0)
  Very mildly ill 69 (35.8) 38 (36.5) 77 (40.1) 33 (32.7)
  Mildly ill 92 (47.7) 49 (47.1) 81 (42.2) 54 (53.5)
  Moderately ill 21 (10.9) 11 (10.6) 23 (12.0) 9 (8.9)
Previous hospitalisations for psychosis, mean (SD) 2.6 (1.2)a 2.9 (1.2)b 2.7 (1.2)a 2.9 (1.2)c
  1. an = 173; bn = 78; cn = 74. CGI-S Clinical Global Impressions–Severity, ER extended release, PANSS Positive and Negative Syndrome Scale, PP paliperidone palmitate, SD standard deviation.